WO2013142571A3 - Assays for the identification of compounds that modulate lipid homeostasis - Google Patents

Assays for the identification of compounds that modulate lipid homeostasis Download PDF

Info

Publication number
WO2013142571A3
WO2013142571A3 PCT/US2013/033094 US2013033094W WO2013142571A3 WO 2013142571 A3 WO2013142571 A3 WO 2013142571A3 US 2013033094 W US2013033094 W US 2013033094W WO 2013142571 A3 WO2013142571 A3 WO 2013142571A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid homeostasis
assays
identification
compounds
homeostasis
Prior art date
Application number
PCT/US2013/033094
Other languages
French (fr)
Other versions
WO2013142571A2 (en
Inventor
Ann-Hwee Lee
Laurie H. Glimcher
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of WO2013142571A2 publication Critical patent/WO2013142571A2/en
Publication of WO2013142571A3 publication Critical patent/WO2013142571A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention describes the role of regulated IRE 1 -dependent decay (RIDD) in modulating lipid homeostasis by degradation of particular lipid metabolism genes and the role of XBPl in modulating lipid homeostasis by regulating the transcriptional activation of particular lipogenic target genes. Methods for identifying modulators of lipid homeostasis based on modulation of IRE 1 -mediated RIDD of lipid metabolism genes or based on modulation of XBPl -mediated transcriptional regulation of lipogenic target genes are provided.
PCT/US2013/033094 2012-03-20 2013-03-20 Assays for the identification of compounds that modulate lipid homeostasis WO2013142571A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613250P 2012-03-20 2012-03-20
US61/613,250 2012-03-20

Publications (2)

Publication Number Publication Date
WO2013142571A2 WO2013142571A2 (en) 2013-09-26
WO2013142571A3 true WO2013142571A3 (en) 2013-12-05

Family

ID=48096222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/033094 WO2013142571A2 (en) 2012-03-20 2013-03-20 Assays for the identification of compounds that modulate lipid homeostasis

Country Status (1)

Country Link
WO (1) WO2013142571A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
EP2992009B1 (en) 2013-05-01 2020-06-24 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
EP3087183B1 (en) * 2013-12-24 2020-08-26 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
WO2015168589A2 (en) 2014-05-01 2015-11-05 Isis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
AU2016343978A1 (en) * 2015-10-29 2018-05-17 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids
WO2017079739A1 (en) 2015-11-06 2017-05-11 Ionis Pharmaceuticals, Inc. MODULATING APOLIPOPROTEIN (a) EXPRESSION
CN112023047A (en) * 2020-08-27 2020-12-04 山东第一医科大学(山东省医学科学院) Application of Surf4 protein and gene thereof as drug target for reducing plasma cholesterol
CN114712514B (en) * 2022-03-03 2023-03-31 浙江大学 Nanometer medicinal preparation for reducing blood fat locally and systemically, and its application
CN115873955A (en) * 2022-12-22 2023-03-31 复旦大学附属中山医院 Kit for evaluating sensitivity of cisplatin in treatment of lung adenocarcinoma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063187A1 (en) * 2004-09-15 2006-03-23 Hotamisligil Gokhan S Modulation of XBP-1 activity for treatment of metabolic disorders
WO2009091815A2 (en) * 2008-01-14 2009-07-23 President And Fellows Of Harvard College Methods for modulating de novo hepatic lipogenesis by modulating xbp-1 activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
ATE211506T1 (en) 1995-01-31 2002-01-15 Bioimage As A METHOD FOR DETECTING BIOLOGICALLY ACTIVE SUBSTANCES
US20040170622A1 (en) 2002-08-30 2004-09-02 President And Fellows Of Harvard College Methods and compositions for modulating XBP-1 activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063187A1 (en) * 2004-09-15 2006-03-23 Hotamisligil Gokhan S Modulation of XBP-1 activity for treatment of metabolic disorders
WO2009091815A2 (en) * 2008-01-14 2009-07-23 President And Fellows Of Harvard College Methods for modulating de novo hepatic lipogenesis by modulating xbp-1 activity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AHN J ET AL: "Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 49, no. 6, 1 December 2008 (2008-12-01), pages 1019 - 1028, XP025760452, ISSN: 0168-8278, [retrieved on 20081201], DOI: 10.1016/J.JHEP.2008.08.012 *
K. S. COLLISON ET AL: "Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease", THE JOURNAL OF LIPID RESEARCH, vol. 50, no. 8, 11 November 2008 (2008-11-11), pages 1521 - 1537, XP055070370, ISSN: 0022-2275, DOI: 10.1194/jlr.M800418-JLR200 *
K. Y. HUR ET AL: "IRE1 activation protects mice against acetaminophen-induced hepatotoxicity", THE EMBO JOURNAL, vol. 30, no. 7, 30 January 2012 (2012-01-30), pages 1357 - 318, XP055070366, ISSN: 0261-4189, DOI: 10.1038/emboj.2011.52 *
KEZHONG ZHANG ET AL: "The unfolded protein response transducer IRE1[alpha] prevents ER stress-induced hepatic steatosis", THE EMBO JOURNAL, vol. 30, no. 7, 6 April 2011 (2011-04-06), pages 1357 - 1375, XP055070347, ISSN: 0261-4189, DOI: 10.1038/emboj.2011.52 *
KEZHONG ZHANG: "Supplemental information - The unfolded protein response transducer IRE1[alpha] prevents ER stress-induced hepatic steatosis", THE EMBO JOURNAL, 6 April 2011 (2011-04-06), pages S1 - S15, XP055070350, Retrieved from the Internet <URL:http://www.nature.com/emboj/journal/v30/n7/extref/emboj201152s1.pdf> [retrieved on 20130709] *

Also Published As

Publication number Publication date
WO2013142571A2 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
WO2013142571A3 (en) Assays for the identification of compounds that modulate lipid homeostasis
EP3661509A4 (en) Methods and compositions for modulating splicing
EP3544435A4 (en) Methods for modulating rna splicing
EP3617784A4 (en) Light modulation device
EP3429401A4 (en) Footwear tensioning system with guide assembly
EP3265563A4 (en) Regulation of gene expression by aptamer-mediated modulation of alternative splicing
EP3310169A4 (en) Methods for modulating rna splicing
EP3289407A4 (en) Polarization independent reflective modulator
EP3436465A4 (en) Modified ionic liquids containing phosphorus
EP3108597A4 (en) Mach-zehnder modulator bias control for arbitrary waveform generation
EP3509645A4 (en) Modulation of liver genes
EP4223317A3 (en) Modulation of complement activity
EP3398267A4 (en) Wavelength division multiplexed polarization independent reflective modulators
EP3497508A4 (en) A near-eye display system including a modulation stack
EP3419630A4 (en) Synthetic composition for microbiota modulation
EP3554606A4 (en) System and method for enhancing learning with neural modulation
EP3417325A4 (en) Optical transmitter with mach-zehnder modulator and method for operating the same
EP3737390A4 (en) Composition for modulating metabolism
WO2015161170A3 (en) Compositions and methods for modulation of smn2 splicing in a subject
EP3642145A4 (en) Tension regulating directly driven roller festoon
EP3737389A4 (en) Method for modulating metabolism
EP3614196A4 (en) Semiconductor mach-zehnder modulator
EP3265870A4 (en) Bias-based mach-zehnder modulation (mzm) systems
EP3231107A4 (en) Electro-optical modulator with bias control
EP3492966A4 (en) Light control film, light control member, vehicle, and electricity supply method for light control film

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13716544

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13716544

Country of ref document: EP

Kind code of ref document: A2